Core Viewpoint - SciSparc Ltd. has mutually terminated its planned merger with AutoMax Motors Ltd., concluding a deal aimed at expanding into Israel's automotive market [1][2]. Loan Repayment Terms - AutoMax is required to repay $4.25 million with 9% annual interest by January 1, 2028, and a separate $2 million loan will be repaid in monthly installments of $60,000 starting November 20, 2025, with an 8% annual interest rate [2]. Background on the Merger - The merger was initially agreed upon in April 2024, with plans for SciSparc to acquire AutoMax through a reverse merger structure. The deal received approval from both companies' shareholders in 2025 [2]. Strategic Focus After Termination - Following the cancellation of the merger, SciSparc will continue to concentrate on its pipeline of treatments for central nervous system disorders and advance drug discovery using quantum algorithms [3]. Price Action - SciSparc shares experienced a premarket increase of 2.32%, trading at $4.86 [4].

Core Viewpoint - SciSparc Ltd. has entered into a framework agreement for the mutual termination of its merger with AutoMax Motors Ltd., which includes repayment terms for outstanding loans [1][2]. Group 1: Termination of Merger - The parties have mutually agreed to terminate the Agreement and Plan of Merger dated April 10, 2024, making it null and void effective immediately [2]. Group 2: Loan Repayment Terms - AutoMax will repay a loan of $4.25 million with 9% annual interest in a lump-sum payment on January 1, 2028 [3]. - AutoMax will also repay a $2.0 million loan in monthly installments of $60,000 starting November 20, 2025, with 8% annual interest, and will pay accrued interest totaling $114,523 at the outset [4]. Group 3: Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders, including treatments for Tourette Syndrome, Alzheimer's disease, and autism spectrum disorder [5].

Core Viewpoint - SciSparc Ltd. experienced a significant stock price increase of 89.13% to $3.48 in after-hours trading following a court-granted stay in merger proceedings with AutoMax Motors Ltd. [1] Group 1: Merger Proceedings - The Jerusalem District Court has granted AutoMax's request to delay merger proceedings until September 30 due to concerns about completing the merger and meeting closing conditions [2] - A merger agreement was signed between SciSparc and AutoMax on April 10, 2024, which has been revised due to operational difficulties at AutoMax [3] Group 2: Stock Performance - In 2025, SciSparc's stock saw a significant decline of 75.66%, with a high of $22.47 on January 6 and a low of $1.80 by Monday, with trading volume dropping to 123,000 shares [4] - The market capitalization of SciSparc is $2.98 million, with the stock trading between $1.75 and $37.59 over the past year, and it remains down 71.87% despite the recent surge [5] - During the regular trading session on Tuesday, the stock experienced a 2.22% increase [5]

Group 1 - SciSparc Ltd. announced the approval of a merger with AutoMax Motors Ltd., enhancing its operations into the automotive sector [1][2] - The merger will result in SciSparc acquiring 100% of AutoMax's share capital through a reverse merger, with SciSparc shareholders expected to hold approximately 50.01% of the combined company's share capital [2][3] - The merger aligns with SciSparc's long-term strategy to diversify its portfolio and capitalize on the expanding electric vehicle market in Israel [3] Group 2 - SciSparc has provided financial support to AutoMax, including a $4.25 million bridge loan in 2024 and an additional $2 million loan in February 2025 [3] - The closing of the merger is subject to customary closing conditions, including approval from the Israeli court [3] - SciSparc is a specialty clinical-stage pharmaceutical company focused on cannabinoid pharmaceuticals, with ongoing drug development programs targeting various disorders [4]

Core Viewpoint - SciSparc Ltd. has announced the approval of a strategic merger with AutoMax Motors Ltd., aiming to enhance shareholder value by diversifying into the automotive sector, particularly focusing on the electric vehicle market in Israel [2][3]. Group 1: Merger Details - The merger will involve SciSparc acquiring 100% of AutoMax's share capital through a reverse merger, with AutoMax continuing as a wholly-owned subsidiary [2]. - Following the merger, SciSparc shareholders are expected to hold approximately 50.01% of the combined company's share capital [2]. - The merger is part of a definitive agreement entered into on April 11, 2024, and marks a significant step in expanding SciSparc's operations [2][3]. Group 2: Financial Support and Strategy - SciSparc has previously supported AutoMax's growth with financial assistance, including a $4.25 million bridge loan in 2024 and an additional $2 million loan in February 2025 [3]. - The merger aligns with SciSparc's long-term strategy to diversify its portfolio and capitalize on the expanding electric vehicle market in Israel [3]. Group 3: Closing Conditions - The closing of the merger is subject to customary closing conditions, including shareholder approvals from both companies and Israeli court approval [4]. - Special meetings for AutoMax's shareholders to vote on the merger approval are scheduled for August 28, 2025 [4]. Group 4: Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, with ongoing drug development programs based on cannabinoid pharmaceuticals [5]. - The company also has a controlling interest in a subsidiary that sells hemp seed oil-based products on the Amazon.com Marketplace [5].

Core Viewpoint - SciSparc Ltd. is progressing with its proposed merger with AutoMax Motors Ltd., which will enhance its portfolio in the electric vehicle sector while maintaining its focus on cannabinoid pharmaceuticals [1][2]. Group 1: Merger Details - SciSparc and AutoMax entered into a merger agreement in April 2024, where SciSparc will acquire 100% of AutoMax's share capital through a reverse merger [2]. - The merger is subject to customary closing conditions, including shareholder approvals from both companies and Israeli court approval [2]. - Special meetings for shareholder votes on the merger are scheduled for August 25, 2025, for SciSparc and August 28, 2025, for AutoMax [2]. Group 2: Regulatory Approvals - The U.S. Securities and Exchange Commission (SEC) declared effective the registration statement on Form F-4 regarding the merger on July 21, 2025 [3]. Group 3: Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, with drug development programs targeting Tourette Syndrome, Alzheimer's disease, and autism spectrum disorder [4]. - The company also has a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon [4].